| Disease | WE HAVE TRIED KOREAN RED GINSENG (KRG,DAILY 5.4 G) TO 16 HIV INFECTED PATIENTS(PT)FOR 47 PLUS MINUS 6 MONTHS(MO) (RANGE, 40-57 MO). FOLLOW UP PERIOD WAS 53 PLUS OR MINUS 9 MO(R,41-69). THE CD4+T CELLS(CD4-T), SERUM BETA2-MICROGLOBULIN (BETA-2M),
SOLUBLE CD8 ANTIGEN (SCD8), AND ICD P24 ANTIGEN (P24) WERE MEASURED EVERY 6 MONTHS AND COMPARED TO THOSE OF CONTROL GROUP (N=10 PTS) WITHOUT KRG OR ANY ANTIRETROVIRAL DRUG. BASELINE CDR+T WAS 301 PLUS OR MINUS 117/MICROLITER (R,131-537) IN KRG
GROUP AND INCREASED TO 362 PLUS OR MINUS 167/MICROLITERS (P IS LESS THAN 0.05), 370 PLUS OR MINUS 190/MICROLITGER (P IS LESS THAN 0.05), 393 PLUS OR MINUS 172/MICROLITERS (P IS LESS THAN 0.01) AND 362 PLUS OR MUNIS 171/MICROLITERS (P=0.07,ON 6,
12, 24 AND 36 MO, RESPECTIVELY. LAST CD4+T INCREASED TO 359 PLUS OR MINUS 215/MICROLITERS (R, 29-921 ON 53 MO, WHEREAS IN CONTROL, CD4-T DECREASED FROM 352 PLUS OR MINUS 133/MICROLITERS TO 156 PLUS OR MINUS 109/MICROLITERS DURING 42 PLUS OR
MINUS 8 MO (R,32-57)(P IS LESS THAN 0.01). TEN OF 12 PTS WITH BASELINE CDR-T GREATER THAN 200/MICROLITERS SHOWED INCREASED LEVEL AT FINAL TEST. PARTICULARLY, 2 OF 10 PTS SHOWED COMPLETE REVERSION OF CD4/CD8 RATIO. THE SCD8 DECREASED FROM 682
PLUS OR MINUS 258 (U/ML) TO 551 PLUS OR MINUS 210 FOR 53 MO IN PTS TREATED WITH KRG (P IS LESS THAN 0.01). BETA2-M ALSO DECREASED FROM 2.48 PLUS OR MINUS 0.8 (MG/L) TO 2.21 PLUS OR MINUS 0.5 (P=0.6). MEAN BODY WEIGHT SIGNIFICANTLY INCREASED
(P IS LESS THAN 0.05). BASELINE P24 WAS POSITIVE FOR 6 PTS WITH KRG. THE LAST P24 DECREASED IN THE 4 TO 6 PTS. OF ALL MARKERS ABOVE, THE CHANGE OF SCD8 BY KRG INTAKE SHOWED DEFINITE CORRELATION. THIS STUDY SUGGESTS THAT KRG HAS DEFINITE LONG-
TERM IMMUNE MODULATING EFFECT WITHOUT SIDE EFFECT ON HIV-INFECTED PATIENTS. |